[{"from": "human", "value": "Describe this molecule. [C][C][O][C][=Branch1][C][=O][C@H1][Branch2][Ring1][O][C][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][N][C][=N][C][=C][C][=C][Ring1][=Branch1][C][=N][C][=C][Ring1][=Branch1][N][C][=C][Branch1][#C][C][=Branch1][C][=O][C][Ring1][Branch1][C][C][C][C][C][Ring1][=Branch1][Br]"}, {"from": "gpt", "value": "The molecule is an antagonist of the vascular cell adhesion molecule 1 (VCAM-1) binding to alpha4-integrins (other adhesion molecules), a process thought to be implicated in the pathophysiology of Multiple Sclerosis (MS). It is considered a small-molecule prodrug. CDP323 was originally developed by the British biopharmaceutical company Celltech plc. (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis."}]